-
2024-515267-59-00
4
2024-04-07
Acute myeloid leukemia
-
2023-504323-25-01
5
2024-03-19
breast cancer
-
2023-508502-18-00
5
2024-03-19
Alport syndrome
-
2023-505141-48-00
5
2024-03-07
Fibrosis
-
2023-507611-35-00
1
2024-03-01
mild to moderate asthma
-
2022-502889-24-00
5
2024-02-13
chemotherapy-induced polyneuropathy (CIPN)
-
2023-503938-52-00
4
2024-01-26
Progressive Glioblastoma
-
2022-503084-15-00
1
2024-01-12
Progressive metastatic solid cancer after failure of established treat
-
2022-502159-78-00
5
2023-12-06
Chronic Spontaneous Urticaria
-
2024-512881-32-00
6
2023-11-22
Psoriasis vulgaris and/or psoriatric arthritis
-
2022-502332-39-00
4
2023-11-15
Tuberous sclerosis complex (TSC)
-
2022-501869-41-00
9
2023-11-14
Acute Lymphoblastic Leukemia, in Relapse
Lymphoblastic Lymphoma (Precu
-
2022-500453-16-00
4
2023-10-30
Multiple Myeloma
-
2023-503582-35-00
6
2023-10-26
Staphylococcus aureus bacteremia
-
2023-503661-28-00
5
2023-10-26
Hidradenitis Suppurativa
-
2022-502117-29-00
5
2023-10-19
Advanced pancreatic cancer
-
2023-503558-10-00
5
2023-10-13
oligometastatic pancreatic cancer
-
2022-502281-25-00
5
2023-09-27
Focal Onset Seizures
-
2022-502357-34-00
5
2023-09-27
Extensive Stage Small Cell Lung Cancer
-
2022-501831-18-00
4
2023-09-13
Patients with hematologic malignancies and undergoing allogenic hemato
-
2024-511336-28-00
9
2023-08-11
Leukemia in childhood
-
2022-503133-54-00
7
2023-08-09
Solid Tumors
-
2024-512320-11-00
5
2023-08-09
Primary diffuse large B-cell lymphoma of the central nervous system
(P
-
2024-517966-40-00
4
2023-07-13
Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::ABL1 positive (Ph